Literature DB >> 15158782

Synthesis, conformation, and immunogenicity of monosaccharide-centered multivalent HIV-1 gp41 peptides containing the sequence of DP178.

Jiahong Ni1, Robert Powell, Ilia V Baskakov, Anthony DeVico, George K Lewis, Lai-Xi Wang.   

Abstract

Several monosaccharide-centered multivalent HIV-1 gp41 peptides containing the sequence of DP178 were synthesized. Conformational studies showed that multivalent assembly enhanced the alpha-helical content of the peptide. Therefore, 2-, 3-, or 4-alpha-helix bundles of peptide DP178 could be obtained by assembling the peptide on a suitable bi-, tri-, or tetravalent template. Immunization studies indicated that while peptide DP178 alone was poorly immunogenic, the tetravalent peptide MVP-1 raised high titers of antibodies in mice that recognize not only peptide DP178 but also the native HIV-1 glycoprotein gp41, even in the absence of a carrier protein or adjuvant. The study suggests that carbohydrate-centered multivalent peptides provide not only a model for mimicking protein alpha-helix-bundle structure, but also an effective immunogen for raising high-titer antibodies against HIV-1 envelope glycoprotein gp41.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15158782     DOI: 10.1016/j.bmc.2004.04.008

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  8 in total

Review 1.  The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design.

Authors:  Marinieve Montero; Nienke E van Houten; Xin Wang; Jamie K Scott
Journal:  Microbiol Mol Biol Rev       Date:  2008-03       Impact factor: 11.056

2.  Enfuvirtide biosynthesis in thermostable chaperone-based fusion.

Authors:  Vladimir Zenin; Maria Yurkova; Andrey Tsedilin; Alexey Fedorov
Journal:  Biotechnol Rep (Amst)       Date:  2022-05-14

3.  Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope.

Authors:  Gail Ferstandig Arnold; Paola K Velasco; Andrew K Holmes; Terri Wrin; Sheila C Geisler; Pham Phung; Yu Tian; Dawn A Resnick; Xuejun Ma; Thomas M Mariano; Christos J Petropoulos; John W Taylor; Hermann Katinger; Eddy Arnold
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

4.  A fusion intermediate gp41 immunogen elicits neutralizing antibodies to HIV-1.

Authors:  Rachel P J Lai; Miriam Hock; Jens Radzimanowski; Paul Tonks; David Lutje Hulsik; Gregory Effantin; David J Seilly; Hanna Dreja; Alexander Kliche; Ralf Wagner; Susan W Barnett; Nancy Tumba; Lynn Morris; Celia C LaBranche; David C Montefiori; Michael S Seaman; Jonathan L Heeney; Winfried Weissenhorn
Journal:  J Biol Chem       Date:  2014-08-26       Impact factor: 5.157

5.  Modulating immunogenic properties of HIV-1 gp41 membrane-proximal external region by destabilizing six-helix bundle structure.

Authors:  Saikat Banerjee; Heliang Shi; Habtom H Habte; Yali Qin; Michael W Cho
Journal:  Virology       Date:  2016-01-21       Impact factor: 3.616

6.  Immunogenic properties of a trimeric gp41-based immunogen containing an exposed membrane-proximal external region.

Authors:  Habtom H Habte; Saikat Banerjee; Heliang Shi; Yali Qin; Michael W Cho
Journal:  Virology       Date:  2015-10-09       Impact factor: 3.616

7.  Current status of multiple antigen-presenting peptide vaccine systems: Application of organic and inorganic nanoparticles.

Authors:  Yoshio Fujita; Hiroaki Taguchi
Journal:  Chem Cent J       Date:  2011-08-23       Impact factor: 4.215

Review 8.  Strategy for Designing a Synthetic Tumor Vaccine: Multi-Component, Multivalency and Antigen Modification.

Authors:  Zhi-Hua Huang; Zhan-Yi Sun; Yue Gao; Pu-Guang Chen; Yan-Fang Liu; Yong-Xiang Chen; Yan-Mei Li
Journal:  Vaccines (Basel)       Date:  2014-07-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.